Ensign Peak Advisors
ATXS

Ensign Peak Advisors’s Astria Therapeutics ATXS Stock Holding History

Ensign Peak Advisors’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-65,000
Closed -$485K – 1742
2023
Q3 		$485K Hold
65,000
– – ﹤0.01% 1601
2023
Q2 		$541K Hold
65,000
– – ﹤0.01% 1614
2023
Q1 		$865K Hold
65,000
– – ﹤0.01% 1357
2022
Q4 		$968K Buy
+65,000
New +$670K ﹤0.01% 1184

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Ensign Peak Advisors's ATXS Position: Q4 2023 in Review

Ensign Peak Advisors sold out of Astria Therapeutics (ATXS) in Q4 2023, closing a stake of 65,000 shares — an estimated $485K sold.

Ensign Peak Advisors first reported a position in ATXS in Q4 2022 and held it in 4 quarters. The position peaked at $968K in Q4 2022. 80 funds tracked by Wall St. Rank hold ATXS as of Q4 2023.

  • Ensign Peak Advisors reported no remaining Astria Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Ensign Peak Advisors sold 65,000 Astria Therapeutics shares in Q4 2023, an estimated $485K.
  • Ensign Peak Advisors first reported a position in Astria Therapeutics in Q4 2022 and held it in 4 quarters.
  • Ensign Peak Advisors's Astria Therapeutics position peaked at $968K in Q4 2022.
  • 80 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2023.

Based on Ensign Peak Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.